Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.
La Clinica terapeutica（2022）
摘要
Non-pegylated liposomal doxorubicin may represent a valid therapeutic option in first-line for elderly patients with HER/2 negative MBC improving survival, anti-tumor response rate and de-creases cardiotoxicity.
更多查看译文
关键词
Ca 15-3,Cyclophosphamide,Elderly woman,Metastatic breast cancer,Non-pegylated liposomal doxorubicin,Quality of life
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要